The estimated Net Worth of Grant Pickering is at least $63.3 Million dollars as of 23 August 2024. Mr Pickering owns over 15,000 units of Vaxcyte stock worth over $56,080,982 and over the last 12 years he sold PCVX stock worth over $6,295,734. In addition, he makes $938,361 as Co-Founder and CEO & Director at Vaxcyte.
Mr has made over 54 trades of the Vaxcyte stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of PCVX stock worth $30,450 on 23 August 2024.
The largest trade he's ever made was exercising 65,000 units of Vaxcyte stock on 11 March 2024 worth over $131,950. On average, Mr trades about 11,668 units every 66 days since 2013. As of 23 August 2024 he still owns at least 493,888 units of Vaxcyte stock.
You can see the complete history of Mr Pickering stock trades at the bottom of the page.
Grant E. Pickering M.B.A. is the Co-Founder, CEO & Director at Vaxcyte.
As the Co-Founder and CEO & Director of Vaxcyte, the total compensation of Mr A at Vaxcyte is $938,361. There are no executives at Vaxcyte getting paid more.
Mr A is 53, he's been the Co-Founder and CEO & Director of Vaxcyte since . There are 2 older and 6 younger executives at Vaxcyte. The oldest executive at Vaxcyte, Inc. is Paul W. Sauer M.B.A., MBA, 60, who is the Sr. VP of Process Devel. & Manufacturing.
Grant's mailing address filed with the SEC is C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070.
Over the last 12 years, insiders at Vaxcyte have traded over $60,439,674 worth of Vaxcyte stock and bought 1,293,000 units worth $20,688,000 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ..., and Llp Abingworth. On average, Vaxcyte executives and independent directors trade stock every 23 days with the average trade being worth of $2,563,959. The most recent stock trade was executed by Jim Wassil on 3 September 2024, trading 10,000 units of PCVX stock currently worth $24,200.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte executives and other stock owners filed with the SEC include: